FDA Clearance Tracker · P140029-S058
Restylane® Contour
Last checked: Nov 20, 2026Latest source record: Sep 18, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Sep 18, 2026
Approved
Time to decision
120 days
Received May 21, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
Device type
- Device type
- Implant, dermal, for aesthetic use (LMH)
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
approval for updated device labeling, including the addition of a statement regarding how the Restylane Contour is only for distribution to providers that have taken and successfully completed device-specific use training program when used for the correction of temple hollowing in patients over the age of 21.
Source documents
Other decisions for Q-Med AB
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Restylane® ContourPMA supplement
P140029-S054 · Decided Mar 20, 2026 · 239 days after receipt · Panel Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.